2014
DOI: 10.4172/2161-0495.1000207
|View full text |Cite
|
Sign up to set email alerts
|

Ex vivo Effects of Sorafenib and Regorafenib on Murine Hepatocytes

Abstract: Sorafenib and regorafenib are structurally-related small-molecular-weight inhibitors of cellular kinases. Regorafenib has a Boxed Warning stating: "Severe and sometimes fatal hepatotoxicity has been observed in clinical trials", while sorafenib is considered less hepatotoxic. This ex vivo study assessed the effects of sorafenib (2.5 and 50 µM) and regorafenib (5.0 and 50 µM) on liver structure, ultrastructure, cellular respiration (mitochondrial O 2 consumption), ATP, caspase activity, urea synthesis, and glut… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2019
2019
2019
2019

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 21 publications
0
1
0
Order By: Relevance
“…Sorafenib and Regorafenib have been used as the target therapy for the treatment of a large range of tumor types [6]. They inhibit tumor cell growth, proliferation, and tumor angiogenesis [7,8].…”
Section: Introductionmentioning
confidence: 99%
“…Sorafenib and Regorafenib have been used as the target therapy for the treatment of a large range of tumor types [6]. They inhibit tumor cell growth, proliferation, and tumor angiogenesis [7,8].…”
Section: Introductionmentioning
confidence: 99%